Authorized purpose: Aortic and iliac artery segmentation, visualization, measurement, and longitudinal tracking as adjunctive physician decision support.
Clinical role
Segmentation, vessel visualization, measurement, and longitudinal-tracking support integrated with physician review; adjunctive to clinical decision-making.
Images and patients
CT/CTA · Aorta, iliac arteries, and major branching vessels in the chest, abdomen, and/or pelvis
Key limitation
Keep in mind: Results are not standalone clinical decisions. Excessive motion or metal implants may reduce output quality. The packet excludes cone-beam CT, non-axial or excessively oblique series, improperly ordered or materially missing slices, inadequate target-zone coverage, and datasets outside the stated FOV, pixel-spacing, slice-spacing, slice-thickness, or 70-150 kVp limits.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Aortic and iliac artery segmentation, visualization, measurement, and longitudinal tracking as adjunctive physician decision support.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Aorta, iliac arteries, and major branching vessels in the chest, abdomen, and/or pelvis Input: DICOM axial CT datasets of the chest, abdomen, and/or pelvis, including NCCT, CECT, CTA, and CTPA, for adults; the packet specifies target-zone, field-of-view, pixel-spacing, slice-spacing, slice-thickness, tube-voltage, and image-order requirements.
Who uses it?Intended users: Radiologists, cardiothoracic surgeons, vascular surgeons, endovascular specialists, ED physicians, or users with similar training
What does the software produce?Output: Aortic and iliac centerline measurements; maximum oblique diameter by aortic zone; fixed aortic and left/right iliac measurements; 3D volume renderings; rotations; iliac CPRs; aortic oblique MPRs; longitudinal tracking; and segmented-vessel visualizations.
What is its most important limitation?Key limitation: Results are not standalone clinical decisions. Excessive motion or metal implants may reduce output quality. The packet excludes cone-beam CT, non-axial or excessively oblique series, improperly ordered or materially missing slices, inadequate target-zone coverage, and datasets outside the stated FOV, pixel-spacing, slice-spacing, slice-thickness, or 70-150 kVp limits.
Clinical takeaway. Clinical role: Aortic and iliac artery segmentation, visualization, measurement, and longitudinal tracking as adjunctive physician decision support.
Evidence takeaway. Evidence from the reviewed source record: FDA performance validation used 108 NCCT, CTA, or CECT/CTPA cases from 115 patients, with up to three clinical experts comparing outputs with source DICOM images. Primary endpoints included 100% agreement for VR segmentation/clinical accuracy, CPR/MPR quality, anatomical labeling, and maximum-oblique-diameter zone location. Quantitative results included average VR Dice 0.93, VR Hausdorff distance 0.54 mm, CPR/MPR Hausdorff distance 0.59 mm, ground-truth reproducibility Dice 0.95, and measurement-report mean absolute error 0.22 cm.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Aortic and iliac artery segmentation, visualization, measurement, and longitudinal tracking as adjunctive physician decision support.
Segmentation, vessel visualization, measurement, and longitudinal-tracking support integrated with physician review; adjunctive to clinical decision-making.
DICOM axial CT datasets of the chest, abdomen, and/or pelvis, including NCCT, CECT, CTA, and CTPA, for adults; the packet specifies target-zone, field-of-view, pixel-spacing, slice-spacing, slice-thickness, tube-voltage, and image-order requirements.
Results are not standalone clinical decisions. Excessive motion or metal implants may reduce output quality. The packet excludes cone-beam CT, non-axial or excessively oblique series, improperly ordered or materially missing slices, inadequate target-zone coverage, and datasets outside the stated FOV, pixel-spacing, slice-spacing, slice-thickness, or 70-150 kVp limits.
FDA performance validation used 108 NCCT, CTA, or CECT/CTPA cases from 115 patients, with up to three clinical experts comparing outputs with source DICOM images. Primary endpoints included 100% agreement for VR segmentation/clinical accuracy, CPR/MPR quality, anatomical labeling, and maximum-oblique-diameter zone location. Quantitative results included average VR Dice 0.93, VR Hausdorff distance 0.54 mm, CPR/MPR Hausdorff distance 0.59 mm, ground-truth reproducibility Dice 0.95, and measurement-report mean absolute error 0.22 cm.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA performance validation used 108 NCCT, CTA, or CECT/CTPA cases from 115 patients, with up to three clinical experts comparing outputs with source DICOM images. Primary endpoints included 100% agreement for VR segmentation/clinical accuracy, CPR/MPR quality, anatomical labeling, and maximum-oblique-diameter zone location. Quantitative results included average VR Dice 0.93, VR Hausdorff distance 0.54 mm, CPR/MPR Hausdorff distance 0.59 mm, ground-truth reproducibility Dice 0.95, and measurement-report mean absolute error 0.22 cm.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Rapid Aortic Measurements regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K251987
Samplen=108
IndependenceIndependence not established
K251987
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K251987. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM axial CT datasets of the chest, abdomen, and/or pelvis, including NCCT, CECT, CTA, and CTPA, for adults; the packet specifies target-zone, field-of-view, pixel-spacing, slice-spacing, slice-thickness, tube-voltage, and image-order requirements.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Rapid Platform provides DICOM filtering, job and interface management, accepts DICOM images, and returns processed DICOM images to the source imaging modality or PACS. The packet describes on-premises installation behind the customer firewall or a hybrid on-premises/cloud configuration; specific local interface compatibility is not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Rapid AM as a module integrated into the Rapid Platform, which can be installed on-premises within the customer's infrastructure behind their firewall or in a hybrid on-premises/cloud configuration. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Rapid AM is integrated into the Rapid Platform which provides common functions and services" … "The Integrated Module and Platform can be installed on-premises within customer’s infrastructure behind their firewall or in a hybrid on-premises/cloud configuration.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Aortic and iliac centerline measurements; maximum oblique diameter by aortic zone; fixed aortic and left/right iliac measurements; 3D volume renderings; rotations; iliac CPRs; aortic oblique MPRs; longitudinal tracking; and segmented-vessel visualizations.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Rapid AM as a module integrated into the Rapid Platform, which can be installed on-premises within the customer's infrastructure behind their firewall or in a hybrid on-premises/cloud configuration. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Rapid AM is integrated into the Rapid Platform which provides common functions and services" … "The Integrated Module and Platform can be installed on-premises within customer’s infrastructure behind their firewall or in a hybrid on-premises/cloud configuration.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Rapid Platform provides DICOM filtering, job and interface management, accepts DICOM images, and returns processed DICOM images to the source imaging modality or PACS. The packet describes on-premises installation behind the customer firewall or a hybrid on-premises/cloud configuration; specific local interface compatibility is not established.
RapidAI's current platform security and compliance one-pager states that its portfolio uses encryption at rest and in transit, role-based access control, monitoring/logging and listed HIPAA, GDPR, ISO 13485, ISO 27001, ISO 27701 and SOC 2 Type 1 claims.
Vendor-wide
Checked 2026-10-25
This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.
RapidAI's security and compliance one-pager (Rev 8, published by iSchemaView, Inc.) states continuous infrastructure monitoring and system telemetry to detect operational anomalies in real time, plus a formal incident response and escalation framework with defined communication protocols.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. No certificate or audit report was read; the one-pager names the RapidAI platform generally and does not scope these commitments to any specific product release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Rapid Aortic Measurements; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor security document, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K251987 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.
Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.